POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)

Condition(s) targeted: Seasonal Allergic Rhinitis

Intervention: Levocetirizine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: UCB

Official(s) and/or principal investigator(s):
Krassimir Mitchev, MD, PhD, Study Director, Affiliation: UCB

Comparative study on clinical efficacy and safety of levocetirizine and desloratadine as measured by the subject's satisfaction/dissatisfaction after one week of treatment

Official title: A Monocenter, Double-Blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen

Study design: Randomized, Double-Blind, Active Control, Parallel Assignment

Primary outcome: Subjects' satisfaction / dissatisfaction after the first week of treatment.

Secondary outcome: allergic rhinitis symptoms scores over the first week of treatment , subject's satisfaction / dissatisfaction of their choice of treatment after the first week of treatment, time to first feeling of (sufficient) symptom improvement during the first we

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Clinical history of SAR known and treated since 2 years.

- Positive skin prick test (wheal > 3 mm larger than the diluent control) or RAST (≥3. 5

IU/ml) to grass pollen (less than 1 year).

- Minimum mean T5SS of 8 during the baseline period.

Exclusion Criteria:

- Have an associated asthma requiring a daily treatment other than β2 short acting

agonist prn

- Have atopic dermatitis or urticaria requiring antihistamine treatment or the

administration of oral or topical corticosteroids and any other disease requiring the administration of oral or topical corticosteroids

Starting date: May 2005
Ending date: July 2005
Last updated: March 6, 2008